Why it was recalled
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
Product description
Losartan Potassium Tablets USP 50 mg, a) 30 count (NDC 23155-645-03), b) 90 count (NDC 23155-645-09) and c) 1000 count (NDC 23155-645-10) bottles, Rx only, Manufactured by: Vivimed Life Sciences Private Limited, Tamil Nadu, India, Manufactured for: Heritage Pharmaceutical Inc., East Brunswick, NJ 08816 NDC 23155-645-09
Lot numbers, UPCs & expiration codes
a) CL018008A, exp Mar 2020; b) CL018008B, exp Mar 2020; c) CL018009A, exp Mar 2020
Where it was sold
Nationwide
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-1103-2020
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- Mar 26, 2020
- FDA report date
- Apr 15, 2020
- Quantity
- a) 2,904; b) 14,316; c) 1,368 bottles
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Avet Pharmaceuticals, Inc.
Original FDA data
Every field from FDA enforcement report D-1103-2020, exactly as published.
Show all FDA fields
- City
- East Brunswick
- State
- NJ
- Status
- Terminated
- Country
- United States
- Event ID
- 85283
- Address
- 1 Tower Center Blvd Ste 1700
- Code information
- a) CL018008A, exp Mar 2020; b) CL018008B, exp Mar 2020; c) CL018009A, exp Mar 2020
- Postal code
- 08816-1145
- Report date
- Apr 15, 2020
- Product type
- Drugs
- Recall number
- D-1103-2020
- Classification
- Class II
- Recalling firm
- Avet Pharmaceuticals, Inc.
- Product quantity
- a) 2,904; b) 14,316; c) 1,368 bottles
- Termination date
- Mar 8, 2021
- Reason for recall
- CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Losartan Potassium Tablets USP 50 mg, a) 30 count (NDC 23155-645-03), b) 90 count (NDC 23155-645-09) and c) 1000 count (NDC 23155-645-10) bottles, Rx only, Manufactured by: Vivimed Life Sciences Private Limited, Tamil Nadu, India, Manufactured for: Heritage Pharmaceutical Inc., East Brunswick, NJ 08816 NDC 23155-645-09
- Distribution pattern
- Nationwide
- Recall initiation date
- Mar 26, 2020
- Initial firm notification
- Letter
- Center classification date
- Apr 7, 2020